Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Transfer rules for high school senior athletes in South Carolina will remain the same for the 2026-27 school year. Athletic directors from around the state on Wednesday voted down an amendment that ...

ZJK Industrial Co., Ltd. (NASDAQ: ZJK) ('ZJK Industrial”, 'ZJK” or the 'Company”), a high-tech enterprise specializing in the manufacturing and sale of precision fasteners, structural parts and other ...

CBSE Class 12 Economics exam 2026 was moderate yet tricky in parts, but what surprised students and teachers most about ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

The CBSE Class 12th Economics Exam Analysis for 2026 provides a detailed review, including the question paper's difficulty level, structure, and expert/student feedback. Check expected performance and ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

Egypt-based Beltone Asset Management has secured initial FRA approval to launch “Fadda”, Egypt’s first silver investment fund with cumulative daily returns, introducing a new alternative asset class ...

CBSE Class 12 Hindi board exam held on March 16; students say questions were clear and syllabus-based, though the paper required careful time management.

The exam was conducted today, March 18. Download the question paper PDF, check the detailed exam analysis, and review the answer key to evaluate your performance.

Expected Result Date. Although CBSE has not yet officially confirmed the result date, past trends suggest that the Class 10 results are usually announce ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.